FDA OKs Velcade for priority review

The FDA on Wednesday granted priority review for the use of injectable myeloma drug Velcade in patients with newly diagnosed multiple myeloma, Cambridge, Mass.-based Millennium Pharmaceuticals announced. The drug, approved to treat multiple myeloma or mantle cell lymphoma in patients who have already received other therapies, is being tested as a first-line treatment for the blood cancer.

View Full Article in:

American City Business Journals · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA